Skip to main content
PMC home page
AAPS PharmSciTech logoLink to AAPS PharmSciTech
. 2001 Jan 11;2(1):11–22. doi: 10.1208/pt020101

Statistical optimization of gastric floating system for oral controlled delivery of calcium

Shoufeng Li 1,✉, Senshang Lin 1, Yie W Chien 1, Bruce P Daggy 2, Haresh L Mirchandani 2
PMCID: PMC2750255  PMID: 14727887

Abstract

The development of an optimized gastric floating drug delivery system is described. Statistical experimental design and data analysis using response surface methodology is also illustrated. A central, composite Box-Wilson design for the controlled release of calcium was used with 3 formulation variables: X1 (hydroxypropyl methylcellulose [HPMC] loading), X2 (citric acid loading), and X3 (magnesium stearate loading). Twenty formulations were prepared, and dissolution studies and floating kinetics were performed on these formulations. The dissolution data obtained were then fitted to the Power Law, and floating profiles were analyzed. Diffusion exponents obtained by Power Law were used as targeted response variables, and the constraints were placed on other response variables. All 3 formulation variables were found to be significant for the release properties (P<,05), while only HPMC loading was found to be significant for floating properties. Optimization of the formulations was achieved by applying the constrained optimization. The optimized formulation delivered calcium at the release rate of 40 mg/hr, with predicted n and T50% values at 0.93 and 3.29 hours, respectively. Experimentally, calcium was observed to release from the optimized formulation with n and T50% values of 0.89 (±0.10) and 3.20 (±0.21) hours, which showed an excellent agreement. The quadratic mathematical model developed could be used to further predict formulations with desirable release and floating properties.

Key Words: Calcium, Gastric floating system, Oral controlled delivery, Statistical optimization, Response surface methodology (RSM)

Full Text

The Full Text of this article is available as a PDF (393.3 KB).

References

  • 1.Moes AJ. Gastroretentive dosage forms. Crit Rev Ther Drug Carrier Syst. 1993;10(2):143–159. [PubMed] [Google Scholar]
  • 2.Menon A, Ritschel WA, Sakr A. Development and evaluation of a monolithic floating dosage form for furosemide. J Pharm Sci. 1994;83(Feb):239–245. doi: 10.1002/jps.2600830225. [DOI] [PubMed] [Google Scholar]
  • 3.Jimenez Castellanos MR, Zia H, Rhodes CT. Design and testing in vitro of a bioadhesive and floating drug delivery system for oral application. Int J Pharm. 1994;105:65–70. doi: 10.1016/0378-5173(94)90236-4. [DOI] [Google Scholar]
  • 4.Watanabe K. Preparation and evaluation of intragastric floating tablet having pH independent buoyancy and sustained release property. Arch Pract Pharm Yakuzaigaku. 1993;53:1–7. [Google Scholar]
  • 5.Desai S, Bolton S. Floating controlled-release drug delivery system: in vitro-in vivo evaluation. Pharm Res. 1993;10(Sep):1321–1325. doi: 10.1023/A:1018921830385. [DOI] [PubMed] [Google Scholar]
  • 6.Thanoo AC, Sunny MC, Jayakrishnan A. Oral sustained-release drug delivery systems using polycarbonate microspheres capable of floating on the gastric fluid. J Pharm Pharmacol. 1993;45(Jan):21–24. doi: 10.1111/j.2042-7158.1993.tb03672.x. [DOI] [PubMed] [Google Scholar]
  • 7.Hilton AK, Deasy PB. In vitro and in vivo evaluation of an oral sustained-release floating dosage form of amoxicillin trihydrate. Int J Pharm. 1992;86(10):79–88. doi: 10.1016/0378-5173(92)90033-X. [DOI] [Google Scholar]
  • 8.Xu WL, Tu XD, Lu ZD. Development of gentamicin sulfate sustained-release tablets remaining-floating in stomach. Yao Hsueh Hsueh Pao. 1991;26(7):541–545. [PubMed] [Google Scholar]
  • 9.Gerogiannis VS, Rekkas DM, Dallas PP, Choulis NH. Floating and swelling characteristics of various excipients used in controlled release technology. Drug Dev Ind Pharm. 1993;19(9):1061–1081. doi: 10.3109/03639049309063001. [DOI] [Google Scholar]
  • 10.Chueh HR, Zia H, Rhodes CT. Optimization of sotalol floating and bioadhesive extended release tablet formulations. Drug Dev Ind Pharm. 1995;21(15):1725–1747. doi: 10.3109/03639049509069261. [DOI] [Google Scholar]
  • 11.Heaney RP. Calcium bioavailability. Bol Asoc Med P R. 1987;79(1):27–29. [PubMed] [Google Scholar]
  • 12.Allen LH. Calcium bioavailability and absorption: a review. Am J Clin Nutr. 1982;35(4):783–808. doi: 10.1093/ajcn/35.4.783. [DOI] [PubMed] [Google Scholar]
  • 13.Pak AY, Harvey JA, Hsu MC. Enhanced calcium bioavailability from a solubilized form of calcium citrate. J Clin Endocrinol Metab. 1987;65(4):801–805. doi: 10.1210/jcem-65-4-801. [DOI] [PubMed] [Google Scholar]
  • 14.Pointillart A, Gueguen L. Meal-feeding and phosphorus ingestion influence calcium bioavailability evaluated by calcium balance and bone breaking strength in pigs. Bone Miner. 1993;21(1):75–81. doi: 10.1016/S0169-6009(08)80122-5. [DOI] [PubMed] [Google Scholar]
  • 15.Nickel K. P. Calcium bioavailability from bovine milk and dairy products in premenopausal women using intrinsic and extrinsic labeling techniques. J Nutr. 2001;126(5):1406–1411. doi: 10.1093/jn/126.5.1406. [DOI] [PubMed] [Google Scholar]
  • 16.Box GEP, Wilson KB. On the experimental attainment of optimum conditions. J Roy Statist Soc. 1951;13(B):1–1. [Google Scholar]
  • 17.Fonner AE, Buck JR, Banker GS. Mathematical optimization techniques in drug product design and process analysis. J Pharm Sci. 1970;59(11):1587–1596. doi: 10.1002/jps.2600591110. [DOI] [PubMed] [Google Scholar]
  • 18.Franz RM, Sytsma JA, Smith BP, Lucisano LJ. In vitro evaluation of a mixed polymeric sustained relase matrix using response surface methodology. J Control Release. 1987;5(Sep):59–172. [Google Scholar]
  • 19.Timmermans J, Moes AJ. Measuring the resultantweight of an immersed test material: I. Validation of an apparatus and a method dedicated to pharmaceutical applications. Acta Pharm Technol. 1990;36(3):171–175. [Google Scholar]
  • 20.Colombo P, Bettini R, Santi P, De Ascentiis A, Peppas NA. Analysis of the swelling and release mechanisms from drug delivery systems with emphasis on drug solubility and water transport. J Control Release. 2001;39(May):231–237. [Google Scholar]
  • 21.Mallow A. L. Some comments on Cp. Technometrics. 1999;15:661–675. doi: 10.2307/1267380. [DOI] [Google Scholar]
  • 22.Murray J. X-STAT Menu. 1992.
  • 23.Schwartz JB, Flamholz JR, Press RH. Computer optimization of pharmaceutical formulations I: General Procedure. J Pharm Sci. 1973;62(7):1165–1170. doi: 10.1002/jps.2600620722. [DOI] [PubMed] [Google Scholar]
  • 24.Timmermans J, Moes AJ. Cutoff size for gastric emptying of dosage forms. J Pharm Sci. 1993;82(Aug):854–854. doi: 10.1002/jps.2600820821. [DOI] [PubMed] [Google Scholar]
  • 25.Oth M, Franz M, Timmermans J, Moes A. The bilayer floating capsule: a stomach-directed drug delivery system for misoprostol. Pharm Res. 1992;9(3):298–302. doi: 10.1023/A:1015870314340. [DOI] [PubMed] [Google Scholar]
  • 26.Ichikawa M, Watanabe S, Miyake Y. A new multiple-unit oral floating dosage system. I: Preparation and in vitro evaluation of floating and sustainedreleased characteristics. J Pharm Sci. 2001;80(11):1062–1066. doi: 10.1002/jps.2600801113. [DOI] [PubMed] [Google Scholar]
  • 27.Timmermans J, Moes AJ. Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: new data for reconsidering the controversy. J Pharm Sci. 1994;83(Jan):18–24. doi: 10.1002/jps.2600830106. [DOI] [PubMed] [Google Scholar]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES